Anticoagulation in Acute Coronary Syndrome-State of the Art
Early intravenous anticoagulation is the corner stone treatment of patients admitted with an acute coronary syndrome: it antagonizes the ongoing coronary thrombosis and facilitates the percutaneous coronary intervention, hence a reduction of mortality and acute stent thrombosis. Unfractionated heparin, enoxaparin, bivalirudin and fondaparinux have been extensively studied in large randomized control trials and meta-analyses with the same objective: reducing the ischemic burden without hiking hemorrhagic events.
Source: Progress in Cardiovascular Diseases - Category: Cardiology Authors: Michel Zeitouni, Mathieu Kerneis, Tarek Nafee, Jean-Philippe Collet, Johanne Silvain, Gilles Montalescot Source Type: research
More News: Angiomax | Angioplasty | Cardiology | Cardiovascular | Coronary Angioplasty | Heart | Lovenox | Percutaneous Coronary Intervention | Thrombosis